DHR And UT School Of Medicine At San Antonio Announce Founding Residency Program Directors

Translate to Spanish or other 102 languages!

Doctors Hospital At Renaissance And School Of Medicine At UT Health Science Center At San Antonio Announce Founding Residency Program Directors

- Advertisement -

Mega Doctor News

Graduate medical education is growing and developing in South Texas. Doctors Hospital at Renaissance (DHR) and the School of Medicine at The University of Texas Health Science Center at San Antonio will announce the hiring of four founding program directors for the proposed residency programs in internal medicine, obstetrics and gynecology, general surgery and family medicine anchored at DHR.

These programs will be under the sponsorship of The University of Texas Health Science Center at San Antonio School of Medicine until The University of Texas Rio Grande Valley School of Medicine attains accreditation.

- Advertisement -

Medical schools across the country have steadily increased admissions over the past several years.

But, the mounting lack of residency programs, at which physicians complete their medical training, is actually causing a decrease in the number of practicing physicians in the United States. More than 500 U.S. medical school graduates did not get matched to a residency program in 2013.

The number of graduates that are unable to enter a residency program is expected to continue to grow unless additional Medicare funding is made available or hospitals are able create positions for residents to complete their training.

The critical need for residency programs and the shortage of primary and specialty care physicians across the Rio Grande Valley prompted DHR to invest millions of dollars to create residency programs that students graduating from medical school can apply to starting in the fall of 2014.

- Advertisement -

On Friday, March 14, in a ceremonial signing, DHR and the UT Health Science Center will officially announce their affiliation and the development of graduate medical education in the Rio Grande Valley. It is during this ceremony that the public will be first introduced to the residency program directors.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

Embolism Treatment Developed at University of Michigan receives FDA clearance 

Patients with persistent blood clots require frequent medical interventions just to survive. Yet despite this critical need, there have been few advancements in how these patients are treated. 

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

The U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.
- Advertisement -